Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04558567 · ClinicalTrials.gov registry record · Phase 4
Vogelxo(R) ABPM Study in Hypogandal Men
A Phase 4 study of Hypogonadism, Male, sponsored by Upsher-Smith Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
- 7
- Study locations
NCT04558567: Completed Phase 4 study of Hypogonadism, Male, sponsored by Upsher-Smith Laboratories.
NCT04558567 is a Phase 4 study of Hypogonadism, Male that has completed, run by Upsher-Smith Laboratories. The registered enrollment target is 122 participants, above the 102-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (20% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04558567, a Phase 4 study of Hypogonadism, Male, has completed, sponsored by Upsher-Smith Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Phase 4 ABPM study in Hypogonadal Men
Primary Outcome
Average SBP will be calculated from ABPM measurements taken twice each hour over the 24-hour period. An ABPM measurement session will be standardized and performed during on-site clinic visits at baseline (before treatment) and on the last day of treatment (week 20) to minimize subject variability.
Conditions Studied
Interventions
- DRUG Vogelxo
Study Locations (7)
Texas
- Upsher-Smith Clinical Trials Site #5 - San Antonio
- Upsher-Smith Clinical Trials Site #8 - San Antonio
Alabama
- Upsher-Smith Clinical Trial Site #6 - Birmingham
California
- Upsher-Smith Clinical Trial Site #2 - Anaheim
Florida
- Upsher-Smith Clinical Trial Site #1 - Miami
New York
- Upsher-Smith Clinical Trials Site #7 - Garden City
South Carolina
- Upsher-Smith Clinical Trials Site #4 - North Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 4 |
What the finished NCT04558567 record still lists
NCT04558567 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 102-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Vogelxo is the first listed.
NCT04558567 lists 7 locations in 6 states (Texas, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT04558567 about?
NCT04558567 is a clinical study titled "Vogelxo(R) ABPM Study in Hypogandal Men". A Phase 4 ABPM study in Hypogonadal Men
What is the current status of trial NCT04558567?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2020-08-28. Estimated completion is 2024-01-11.
What conditions does trial NCT04558567 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT04558567?
The interventions under investigation include: Vogelxo (DRUG).
Who is sponsoring clinical trial NCT04558567?
This trial is sponsored by Upsher-Smith Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04558567 being conducted?
This trial has 7 study locations across Alabama, California, Florida, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04558567's enrollment target sits among peer trials
122 5th of 12 higher than 8 of 12 other Hypogonadism, Male trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism, Male trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
COMPLETED · Phase 4
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI